To include your compound in the COVID-19 Resource Center, submit it here.
Bristol-Myers will acquire Amira for $325 million in cash, plus up to $150 million in milestones. Bristol-Myers will gain Amira's AM152, an oral
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury